World's First Experience of the Low-dose radionuclide inhalation therapy in the treatment of COVID-19-associated viral pneumonia: phase 1/2 clinical trial.
Peter ShegayAlexey LeontyevDenis BaranovskiiGerman DavydovMarina PoluektovaLyudmila GrivtsovaVasily PetrievValeriy StepanenkoIgor GulidovValeriy KrylovSvetlana OsadchayaVladimir PetrovMaria SedovaMikhail VekilyanOlga KrasilnikovaSergey MorozovSergey IvanovIlya KlabukovAndrey KaprinPublished in: Current radiopharmaceuticals (2023)
Inhaled low-dose radionuclide therapy of 99mTc aerosol affects the major prognostic indicators of COVID-19-related pneumonia restraining inflammatory response. Overall, we identified no evidence of major adverse events in the group receiving radionuclide.
Keyphrases